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Study objectives: We evaluate the accuracy of pleural interleukine-6 (IL-6), transforming
growth factor-beta 1 (TGF-b1), and vascular endothelial growth factor (VEGF) levels for differ-
entiating benign from malignant pleural exudates.
Patients and methods: Levels of IL-6, TGF-b1, and VEGF were measured by ELISA in 103
patients with non neutrophilic (<50%) exudative pleurisy including both benign and malignant
effusions. Pleurisies were splitted into benign and malignant according to the pathological
diagnosis.
Results: Thirty-nine benign (seven infections; 32 inflammatory diseases) and 64 malignant (34
extrathoracic tumors; 25 lung cancers; five mesotheliomas) pleural exudates were diagnosed
by thoracoscopy. Pleural reticulo-monocyte count, protein Light’s ratio and lactic dehydroge-
nase Light’s ratio were significantly higher in malignant than in benign effusions (p< 0.05,
p< 0.001 and p< 0.001, respectively). The median (range) level of VEGF was significantly
higher in malignant than in benign effusions (664.50 pg/ml [10e40,143] vs 349 pg/ml [10e
8888]) (p< 0.05). VEGF levels correlated with pleural LDH (rZ 0.41, p< 0.0001), glucose
(rZ0.30, p< 0.01) and red cell count (rZ 0.57, p< 0.0001).
No significant difference was found between malignant and benign effusions with respect to
IL-6 (26.8 ng/ml [1.8e421] vs 18.4 ng/ml [0.45e400], respectively) and TGF-b1 (1079 pg/ml
[18e6206] vs 1123 pg/ml [34e5447]) levels.
ROC analysis between benign and malignant pleurisies for VEGF showed an area under the
curve of 619 (pZ 0.03) with a value of 382 pg/ml as the best threshold for distinguishing
benign from malignant effusions.3667881; fax: þ32 43668846.
e (B.C. Duysinx).
8 Elsevier Ltd. All rights reserved.
Cytokines in pleural malignancies 1709Conclusions: Malignant effusions may enhance the release of VEGF in pleural space and its
measurement may help in the diagnosis of malignant effusion.
ª 2008 Elsevier Ltd. All rights reserved.Introduction
Pleural effusion occurs as a complication of many different
diseases and accurate diagnosis is difficult without resorting
to invasive procedures. Particularly, the diagnosis of malig-
nant pleural effusion is sometimes a challenging medical
problem because differentiation from benign effusion is
often difficult with the currently available parameters
derived from thoracocentesis. Although being essential for
distinguishing between transudate and exudate,1 biochem-
ical, microbiological and cytological pleural fluid analyses
have poor value for identifying the cause of a pleural
lymphocytic exudate.2 The sensitivity of cytological exami-
nation of pleural fluid and blind needle biopsy, even when
combined together, is generally less than 75%.3e7 Moreover
there is a lack of accepted and reliable diagnosis criteria
particularly for malignancy based on morphological imaging
(CT and MR imaging).3,8e10 Metabolic imaging has shown its
usefulness11e14 but the technique is not yet largely applied
because of the financial burden of the material needed.
The development of inflammation in the pleura results in
an increased vascular permeability and pleural liquid
accumulation is the result of increased fluid production
and/or reduced lymph drainage. This pleural fluid is
enriched in proteins, inflammatory cells and mediators.3,15
Cytokine-producing cells and cytokines have been reported
in pleural effusions from patients with malignant as well as
benign diseases.15e21
Interleukine-6 (IL-6) is a multifunctional cytokine
secreted by lymphoid and non lymphoid cells that regulates
B cell and T cell function and is a potent inducer of the
acute-phase protein response.22e24 Conflicting results have
been reported regarding the ability of IL-6 in distinguishing
malignant from benign pleural effusion.19,20,25
Transforming growth factor-beta 1 (TGF-b1) is a multi-
functional cytokine that stimulates cell proliferation and
angiogenesis in areas of inflammation26 and increases the
permeability of mesothelial cells.27 TGF-b1 is produced by
and acts on mesothelial cells in an autocrine loop. There-
fore this mediator may be central in the pathogenesis of
pleural diseases. High levels of TGF-b1 have been demon-
strated in both malignant and infectious pleural effu-
sions.28,29 Furthermore, TGF-b1 is a potent fibrogenic
cytokine that contributes to fibrin deposition and tissue
fibrosis in loculated pleural effusion.30
Finally, vascular endothelial growth factor (VEGF) is
a key cytokine in the control of vascular permeability and is
thought to be important in pleural fluid formation.31 VEGF
is able to increase angiogenesis and enhance the perme-
ability of vascular endothelial cells.32,33 High VEGF
concentrations in pleural effusions were found in malig-
nancies including metastasis of the lung or other primary
tumors.34
In this study we have wondered whether the determi-
nation of IL-6, TGF-b1, or VEGF pleural fluid levels mighthelp in identifying the etiology of non neutrophilic pleural
effusions and in particular in differentiating malignant from
benign effusions.
Materials and methods
Patient selection
Two hundred and seventeen consecutive patients presenting
with pleural exudative effusion after thoracocentesis were
diagnosed in our CHU pneumology unit between 2003 and
2006. In the chemical analysis, pleural effusion was consid-
ered as an exudate according to Light’s criteria,1 that is if
pleural effusion met at least one of the following criteria:
a ratio of pleural fluid protein to serum protein greater than
0.5; a ratio of pleural fluid lactic dehydrogenase to serum
lactic dehydrogenase greater than 0.6; pleural fluid lactic
dehydrogenase level greater than two-thirds of the upper
limit of the normal value for serum lactic dehydrogenase.
Neutrophilic pleurisy (>50% neutrophils)2 and empyema
were not included in this study. The neutrophilic pleural
effusions accounted for 53 out of the 217 cases (24%). Addi-
tionally among the non neutrophilic exudates, 61 patients
(28%) had received a diagnosis based on radiological evalu-
ation and thoracocentesis. The patients selected for this
study were those 103 patients (mean age of 66 13.9 years;
range 18e96 years; 62males and 41 females) presentingwith
a non neutrophilic exudative pleural effusion in whom the
combination of chest X-ray, thoracic CT scanning (PQ 2000
4th generation, Picker, Cleveland, Ohio, USA) and thor-
acocentesis failed to give an etiologic diagnosis, thus justi-
fying the realization of a thoracoscopy with pleural biopsies.
This group represented 48% of all pleural effusions. In our
series the thoracoscopy procedure allowed to establish
a diagnosis in each case.
Pleural fluid analysis
A successful thoracocentesis of pleural fluid was performed
on each subject before thoracoscopy was carried out. A
first sample was subjected to routine biochemical analysis
including tests for pleural protein, glucose, lactic dehy-
drogenase (LDH), and amylase levels. A second sample was
added to a tube containing ethylenediamino-tetraic-
potassium anticoagulant for differential cell counting.
For cytokine measurement, the pleural fluid was
centrifuged at 400 g for 10 min, at 4 C. The supernatant
was discarded and kept at 70 C until ELISA was per-
formed. IL-6, TGF-b1 and VEGF cytokines were measured
according to the following commercially available enzyme-
linked immunosorbent assay (ELISA) kits (Cytoset; Bio-
source, Camarillo, USA for IL-6; Duoset; R and D Systems
Europe, Abingdon, UK for TGF-b1 and VEGF). The limit of
detection was 10 pg/ml for each of the three cytokines.
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The final diagnosis of the pleural effusion was obtained by
invasive pleural biopsy during a thoracoscopy. When
a diagnosis of benign disease was established, the patients
were followed for at least 18 months to ensure the absence
of malignant pleural process. Benign pleural effusions were
divided into infectious (parapneumonic and tuberculosis) vs
inflammatory pleurisy. Malignant pleural effusions were
divided into three groups: (1) pleural metastasis of extra-
thoracic cancer, (2) pleural metastasis of primary lung
cancer, (3) mesothelioma.
The size of the pleural effusion was estimated in each
patient by the total pleural fluid volume aspirated when
starting the thoracoscopy procedure. The protocol was
approved by the ethics committee, and informed consent
was obtained from each subject before the study.
Statistical analysis
Characteristics of the pleural fluid and pleural cell counts in
malignant vs benign pleural effusions were compared using
the non parametric ManneWhitney test. For correlations
between variables, we used the Spearman rank coefficient
of correlation. The accuracy of each pleural cytokine to
distinguish malignant from benign pleural lesions was
calculated with receiver operating characteristics (ROC)
analyses. Fisher’s exact test was performed to evaluate the
use of two or three Light’s criteria as cut-off for dis-
tinguishing neoplasic from benign pleural effusion. A p
value <0.05 was considered as statistically significant.
Results
Thoracoscopic biopsies showed benign lesions in 39 patients
and malignant pleural effusions in 64. The mean age was
65 15 years in the benign group and 66 13 years in the
malignant group. The sex ratio was different with females
accounting for 50% of the malignant group while only rep-
resenting 23% in the benign group (p< 0.01). In the malig-
nant group, 34 were metastases of extrathoracic tumors: 11Table 1 Pleural cell count and biochemical parameters in mali
Benign pleural e
RBC/mm3 7200 [40e340,0
WBC/mm3 640 [117e14,92
Neutrophils (%) 6 [0e47]
Lymphocytes (%) 67 [4e98]
Reticulo-monocytes (%) 12.5 [0e78]
Eosinophils (%) 0 [0e40]
Proteins (g/l) 39 [24e59]
LDH (UI/l) 443 [105e9987]
Amylase (UI/l) 38 [12e22,540]
Glucose (g/l) 0.86 [0.02e1.94
Protein Pl/Sg ratio 0.57 [0.33e0.82
LDH Pl/Sg ratio 0.97 [0.15e21.6
Values are expressed as median (range).
*p< 0.05; **p< 0.01; ***p< 0.001; ****p< 0.0001.breast cancers, four ovarian cancers, four kidney cancers,
four pancreatic cancers, four colic tumors, two prostatic
neoplasms, one skin cancer, one genital carcinoma, one
acute leukemia, one laryngeal cancer and one unknown
primary carcinoma. Twenty-five pleural effusions were
secondary to a pleural invasion of a lung cancer (five
squamous non small cell carcinomas, 18 adenocarcinomas,
one large cell carcinoma and one small cell cancer) and
mesothelioma was diagnosed in five patients. Among the
benign pleural diseases, the clinical context, bacteriolog-
ical and histological data led to a final diagnosis of infection
in seven patients (five parapneumonic pleurisies, two
tuberculosis) and inflammatory effusion in 32 patients (one
Dressler’s syndrome, one chronic pancreatitis, two heart
failures, one post-radic pleurisy, five benign asbestos
pleurisies, one uremic pleurisy and 21 non specific chronic
inflammatory changes). So far the follow up of all these
patients with benign pleural disease has been at least 18
months with no disease recurrence or change to pleural
malignancy diagnosis.
There was no significant difference in pleural protein,
LDH, glucose and amylase levels between malignant and
benign pleural effusions. However, protein Light’s ratio and
LDH Light’s ratio were significantly higher in malignant
effusions (p< 0.001 for both). Malignant effusions exhibi-
ted a greater proportion of reticulo-monocyte cell counts
(p< 0.05) (Table 1).
None of the pleural samples showed a positive bacterial
growth during the culture even when the pleural effusion
was deemed to be of infectious origin.
The median level of pleural VEGF was 664.5 pg/ml [10e
40,143] in patients with malignant pleural effusions and
significantly higher compared to the value of 349 pg/ml
[10e8888] found in benign effusions (Table 2 and Fig. 1). By
contrast no significant difference was found in IL-6 and
TGF-b1 pleural levels between malignant and benign effu-
sions (Table 2).
Receiver operating characteristic curves are presented
in Fig. 2. Only the measurement of VEGF showed a signifi-
cant performance in distinguishing between malignant and
benign effusions with an area under the curve (AUC) of 619
(p< 0.05). Derived from this curve, the best cut-point wasgnant and benign pleural effusions
ffusions Malignant pleural effusions
00] 5220 [10e940,000]
0] 710 [4e1000]
11 [0e48]
50 [0e98]
23 [0e87]*
0.5 [0e43]
42 [10e61]
551 [155e3859]
43 [5e903]
] 0.84 [0.18e1.69]
] 0.63 [0.41e0.88]***
] 1.53 [0.47e7.57]***
Table 2 Comparison of pleural cytokine levels between
benign and malignant pleural effusions
Pleural
cytokines
Benign pleurisy
(NZ 39)
Malignant pleurisy
(NZ 64)
IL-6 (ng/ml) 18.41 [0.45e400] 26.83 [1.82e421]
TGF-b (pg/ml) 1123 [34e5447] 1079 [18e6206]
VEGF (pg/ml) 349 [10e8888] 664.50 [10e40,143]*
Values are expressed as median (range).
*p< 0.05; **p< 0.01; ***p< 0.001; ****p< 0.0001.
Figure 2 Receiver operating characteristics (ROC) curves for
differential diagnosis of pleural effusion (malignant vs benign)
by IL-6, TGF-b1 and VEGF.
Cytokines in pleural malignancies 1711found to be 382 pg/ml that gave a sensitivity, specificity
and accuracy of 69%, 54% and 63% respectively. It was
possible to use Light’s criteria to distinguish neoplasic from
benign pleural effusions as long as we used the presence of
the three criteria as cut-off (Table 3). Combining the three
Light criteria gave a relative risk (RR) of 1.97 (95% CI e
1.16e3.34, p< 0.05) for having malignant effusion and
sensitivity, specificity and accuracy of 62%, 64% and 63%
respectively.
VEGF and IL-6 levels did not differ according to the three
sub-groups of malignant effusions. However there was
a strong trend of a raised level of TGF-b1 among the
patients suffering from a mesothelioma (1698 pg/ml [699e
4415]) as compared to those suffering from lung cancer
{767 pg/ml (130e2149)} (pZ 0.06). We found no significant
difference in the three cytokines levels according to the
etiology of benign effusions.
Pleural VEGF levels were positively correlated with LDH
(rZ 0.41, p< 0.0001) but negatively correlated with
glucose (rZ0.30, p< 0.01) (Fig. 3). No correlation was
found with the total pleural proteins levels (rZ0.12,
p> 0.05). Pleural VEGF levels strongly correlated with
pleural red cell counts (rZ 0.57, p< 0.0001) (Fig. 3) but
not with pleural leukocytes (rZ0.114, p> 0.05). Finally,
pleural VEGF levels strongly correlated with the pleural
effusion volume (rZ 0.42, p< 0.0001) (Fig. 3). These
correlations may reflect the aggressiveness and clinical
presentation of the effusion.Figure 1 Comparison of pleural VEGF levels in malignant vs
benign pleural effusions. The dashed line represents the limit
of detection of our assay. The solid line represents the median
value in benign and malignant pleurisy.Discussion
Diagnosing the etiology of pleural lymphocytic exudate is
sometimes a challenging medical problem because of a lack
accuracy of non invasive investigations.2e10 Identifying new
biochemical fluid markers is therefore suitable for differ-
entiating benign from malignant lesions. Our study shows,
in a large and well characterized population of patients
with lymphocytic exudate, that although greater in malig-
nant pleural effusions, pleural VEGF level is of a rather
limited clinical interest in distinguishing between malignant
from benign pleural effusion.
VEGF is a multifunctional cytokine that increases
vascular permeability and it is an important angiogenic
and lymphogenic factor.35,36 Literature has produced
conflicting results about pleural VEGF levels in malig-
nancies so far.31,34,36e41 Part of these discrepancies may
be explained by the selection criteria of pleural effusion
and the nature of the comparisons performed by the
authors to single out the malignant cases. In our study we
took care to exclude transudate and highly neutrophilicTable 3 Fisher’s exact test for the use of three Light’s
criteria as cut-off for distinguishing neoplasic from benign
pleural effusion
Number of
Light’s
criteria
Benign
pleurisy
(NZ 39)
Malignant
pleurisy
(NZ 64)
Total
(NZ 103)
2 24% 23% 47%
3 14% 39% 53%
38% 62% 100%
pZ 0.0142.
Figure 3 Correlation between pleural VEGF levels and pleural effusion volume (a), pleural red cell count (b), pleural glucose
(c) and LDH (d). r is the Spearman coefficient of correlation. The dashed line represents the limit of detection of our assay.
1712 B.C. Duysinx et al.effusions thereby excluding acute bacterial pleural
infection reported to be associated with high VEGF
levels.42 In contrast Daniil et al.42 compared neoplasic
effusions to effusion occurring in an infectious setting
(tuberculosis and parapneumonic effusions). On the other
hand Cheng et al.39 as well as Kaya et al.41 compared
a limited number of malignant effusions to various
miscellaneous pleural diseases including infection. The
goal of our study was to assess the value of cytokines in
pleural effusion where etiology is not obvious. In these
patients we found that malignant effusions were char-
acterized by raised VEGF levels. The raised VEGF levels
found here in malignant effusions confirm some of the
previous studies.31,34,37e39 ROC curve analysis indicates
that 382 pg/ml yields the best accuracy (63%), although
we recognize it to be fairly modest as a diagnostic tool.
When targeting a specificity of 80%, our ROC curve yields
a sensitivity greater than 22%. This level of accuracy
however can be compared to that of other techniques of
investigation such as chest CT scan, the sensitivity of
which may range from 22% to 35% according to the
morphologic chosen criterion43 when specificity is around
80%. In contrast to previous data, no difference was
observed between the different sub-groups of malignant
pleural effusions split according to histology31 or primary
tumor localization.37 We are confident about our results
as our series is larger than the ones which previously
reported differences according to lung histology and
primary localization.The reason why VEGF is increased in malignant effusions
is not clear. Although we cannot exclude that raised VEGF
levels may partly be related to raised pleural endothelial
permeability, the lack of a correlation between pleural
VEGF and protein levels suggests that there may be addi-
tional mechanisms. Local production of VEGF by mesothe-
lial cells, recruited inflammatory cells and malignant cells
is likely to contribute to the raised levels found in malig-
nant effusions.44 In our study we found no correlation
between inflammatory cell counts and VEGF suggesting that
recruited leucocytes may not be central in local VEGF
production. By contrast the positive correlation between
pleural LDH, a marker of tumor activity, and VEGF supports
the hypothesis that malignant cells may contribute to the
production of VEGF and is in line with Cheng et al.37
Interestingly we found an inverse relationship between
pleural glucose and VEGF levels. This supports the idea that
VEGF is raised when metabolic activity of the pleura is
intense as in cancer involvement.11e14 Additionally we
found a strong correlation between pleural red cell counts
and VEGF levels which is in line with the role of VEGF in
pleural neoangiogenesis, a phenomenon present in tumor
proliferation.
In contrast to VEGF, neither TGF-b1 nor IL-6, although
readily detectable, was not found to be increased in the
pleural effusion of malignancies. TGF-b1 was previously
associated with loculated effusions,45 tuberculosis and
mesothelioma.28 In our series most of the effusions
were not loculated, as proved by thoracoscopy, and
Cytokines in pleural malignancies 1713mesothelioma only represented 8% of the malignant cases.
As far as IL-6 is concerned, this cytokine has traditionally
been associated with acute46 or chronic pleural infection.47
Our results indicate that the cytokine is not specifically
associated with a tumoral process.
In conclusion our results show that malignant pleural
effusions display raised VEGF levels which might contribute
to the local growth of the tumor. Because of the modest
accuracy, this finding may have, on its own, limited diag-
nostic value, but may open the way to a new treatment
strategy using anti-VEGF in malignant pleural diseases.
References
1. Light RW, Macgregor MI, Luchsinger PC, Ball Jr WC. Pleural
effusions: the diagnostic separation of transudates and
exudates. Ann Intern Med 1972;77:507e13.
2. Light RW, Erozan YS, Ball WC. Cells in pleural fluid. Their value
in differential diagnosis. Arch Intern Med 1973;132:854e60.
3. Sahn S. State of the art: the pleura. Am Rev Respir Dis 1988;
138:184e234.
4. Prakash U, Reiman H. Comparison of needle biopsy with cyto-
logic analysis for the evaluation of pleural effusion: analysis of
414 cases. Mayo Clin Proc 1985;60:158e64.
5. Von Hoff D, Di Volsi V. Diagnostic reliability of needle biopsy of
the parietal pleura: a review of 272 biopsies. Am J Clin Pathol
1979;72:48e51.
6. Scho¨nfeld N, Loddenkemper R. Pleural biopsy and thoraco-
scopy. Eur Respir Mon 1998;9:135e52.
7. Poe RH, Israel RH, Utell MJ, Hall WJ, Greenblatt DW, Kallay MC.
Sensitivity, specificity and predictive values of closed pleural
biopsy. Arch Intern Med 1984;144:325e8.
8. Dedrick CG, Mc Loud TC, Shepard JA, Shipley RT. Computed
tomography of localized pleural mesothelioma. Am J Roent-
genol 1985;144:275e80.
9. Leung A, Muller N, Miller R. CT in differential diagnosis of
diffuse pleural disease. Am J Roentgenol 1990;154:487e92.
10. Sahn S. Malignant pleural effusions. In: Fischman AP, editor.
Pulmonary diseases and disorders. 2nd ed. New York: Mc Graw-
Hill; 1988. p. 2159e70.
11. Gupta NC, Rogers JS, Graeber GM, Gregory JL, Waheed U,
Mullet D, et al. Clinical role of F-18 fluorodeoxyglucose posi-
tron emission tomography imaging in patients with lung cancer
and suspected malignant pleural effusion. Chest 2002;122(6):
1918e24.
12. Schaffler GJ, Wolf G, Schoellnast H, Groell R, Maier A, Smolle-
Juttner FM, et al. Non-small cell lung cancer: evaluation of
pleural abnormalities on CT scans with 18F-FDG PET. Radiology
2004;231(3):858e65.
13. Duysinx B, Nguyen D, Louis R, Cataldo D, Belhocine T,
Bartsch P, et al. Evaluation of pleural disease with 18-fluo-
rodeoxyglucose positron emission tomography imaging. Chest
2004;125(2):489e93.
14. Duysinx BC, Larock MP, Nguyen D, Corhay JL, Bury T, Hustinx R,
et al. 18F-FDG PET imaging in assessing exudative pleural
effusions. Nucl Med Commun 2006;27:971e6.
15. Antony VB, Godbey SW, Kunkel SL, Hott JW, Hartman DL,
Burdick MD, et al. Recruitment of inflammatory cells to the
pleural space: chemotactic cytokines, IL-8, and monocyte
chemotactic peptide-1 in human pleural fluids. J Immunol
1993;151:7216e23.
16. Alexandrakis MG, Coulocheri SA, Bouros D, Mandalaki K,
Karkavitsas N, Eliopoulos GD. Evaluation of inflammatory
cytokines in malignant and benign pleural effusions. Oncol Rep
2000;7:1327e32.
17. Hoheisel G, Izbicki G, Roth M, Chan CH, Reichenberger F,
Schauer J, et al. Proinflammatory cytokine levels in patientswith lung cancer and carcinomatous pleurisy. Respiration
1998;65:183e6.
18. Shimokata K, Saka H, Murate T, Hasegawa Y, Hasegawa T.
Cytokine content in pleural effusion: comparison between
tuberculous and carcinomatous pleurisy. Chest 1991;99:
1103e7.
19. Yokoyama A, Kohno N, Fujino S, Abe M, Ishida O, Hiwada K.
Soluble interleukine-6 receptor levels in pleural effusions.
Respir Med 1996;90:329e32.
20. Alexandrakis MG, Coulocheri SA, Bouros D, Eliopoulos GD.
Evaluation of ferritin, interleukin-6, interleukin-8 and tumor
necrosis factor-a in the differentiation of exudates and tran-
sudates in pleural effusions. Anticancer Res 1999;19:3607e12.
21. Xirouchaki N, Tzanakis N, Bouros D, Kyriakou D, Karkavitsas N,
Alexandrakis M, et al. Diagnostic value of interleukin-1a,
interleukin-6, and tumor necrosis factor in pleural effusions.
Chest 2002;121:815e20.
22. Opal SM, DePalo VA. Anti-inflammatory cytokines. Chest 2000;
117:1162e72.
23. Nicod LP. Cytokines: l. overview. Thorax 1993;48:660e7.
24. Elias JA, Freundlich B, Kern JA, Rosenbloom J. Cytokine
networks in the regulation of inflammation and fibrosis in the
lung. Chest 1990;97:1439e45.
25. Lin CC, Liu CC, Lin CY. Changes in cell population and tumor
necrosis factor, interleukin-6, and interleukin-8 in malignant
pleural effusions after treatment with intrapleural tetracy-
cline. Am Rev Respir Dis 1993;147:1503e6.
26. Sporn MB, Robert AB, Wakefield LM, de Crombrugghe B. Some
recent advances in the chemistry and biology of transforming
growth factor-beta. J Cell Biol 1987;105:1039e45.
27. Ikubo A, Morisaki T, Katano M, Kitsuki H, Anan K, Uchiyama A,
et al. A possible role of TGF-b in the formation of malignant
effusions. Clin Immunol Immunopathol 1995;77:27e32.
28. Maeda J, Ueki N, Ohkawa T, Iwahashi N, Nakano T, Hada T,
et al. Transforming growth factor-beta 1 (TGF-b1)- and b2-like
activities in malignant pleural effusions caused by malignant
mesothelioma or primary lung cancer. Clin Exp Immunol 1994;
98:319e22.
29. Marie C, Losser M-R, Fitting C, Kermarrec N, Payen D,
Cavaillon JM. Cytokines and soluble cytokine receptors in
pleural effusions from septic and non septic patients. Am J
Respir Crit Care Med 1997;156:1515e22.
30. Border WA, Noble NA. Transforming growth factor-b in tissue
fibrosis. N Engl J Med 1994;331:1286e92.
31. Thickett DR, Armstrong L, Millar AB. Vascular endothelial
growth factor (VEGF) in inflammatory and malignant pleural
effusions. Thorax 1999;54:707e10.
32. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS,
Dvorak HF. Tumor cells secrete a vascular permeability factor
that promotes accumulation of ascites fluid. Science 1983;219:
983e5.
33. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel
heparin-binding growth factor specific for vascular endothelial
cells. Biochem Biophys Res Commun 1989;161:851e8.
34. Sack U, Hoffmann M, Zhao XJ, Chan KS, Hui DS, Gosse H, et al.
Vascular endothelial growth factor in pleural effusions of
different origin. Eur Respir J 2005;25:600e4.
35. Grove CS, Lee YC. Vascular endothelial growth factor: the key
mediator in pleural effusion formation. Curr Opin Pulm Med
2002;8:294e301.
36. Light RW, Hamm H. Malignant pleural effusion: would the real
cause please stand up? Eur Respir J 1997;10:1701e2.
37. Cheng D, Rodriguez RM, Perkett EA, Rogers J, Bienvenu G,
Lappalainen U, et al. Vascular endothelial growth factor in
pleural fluid. Chest 1999;116:760e5.
38. Lim SC, Jung SI, Kim YC, Park KO. Vascular endothelial growth
factor in malignant and tuberculous pleural effusions. J Korean
Med Sci 2000;15:279e83.
1714 B.C. Duysinx et al.39. Cheng D, Lee YC, Rogers JT, Perkett EA, Moyers JP,
Rodriguez RM, et al. Vascular endothelial growth factor level
correlates with transforming growth factor-b isoform levels in
pleural effusions. Chest 2000;118:1747e53.
40. Mommi H, Matsuyama W, Inoue K, et al. Vascular endothelial
growth factor and proinflammatory cytokines in pleural effu-
sions. Respir Med 2002;96:817e22.
41. Kaya A, Poyraz B, Celik G, Ciledag A, Gulbay BE, Savas H,
et al. Vascular endothelial growth factor in benign and
malignant pleural effusions. Arch Bronconeumol 2005;41:
376e9.
42. Daniil ZD, Zintzaras E, Kiropoulos T, Papaioannou AI,
Koutsokera A, Kastanis A, et al. Discrimination of exudative
pleural effusions based on multiple biological parameters. Eur
Respir J 2007;30:957e64.43. Yilmaz U, Polat G, Sahin N, Soy O, Gulay U. CT in differential
diagnosis of benign and malignant pleural disease. Monaldi
Arch Chest Dis 2005;63:17e22.
44. Lee YCG. Cytokines in pleural diseases. Chapter 6. In:
Light RW, Lee YCG, editors. Textbook of pleural disease.
London: Arnold Publishers; 2003. p. 63e89.
45. Chung C-L, Chen C-H, Sheu J-R, et al. Proinflammatory cyto-
kines, transforming growth factor-b1, and fibrinolytic enzymes
in loculated and free-flowing pleural exudates. Chest 2005;
128:690e7.
46. Akarsu S, Kurt AN, Dogan Y, et al. The differential diagnostic
values of cytokine levels in pleural effusions. Mediators
Inflamm 2005;2005(1):2e8.
47. Yokoyama A, Maruyama M, Ito M, et al. Interleukin 6 activity in
pleural effusion. Chest 1992;102:1055e9.
